CWA
HBIO icon

CM Wealth Advisors’s Harvard Bioscience HBIO Stock Holding History

CM Wealth Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,184
Closed -$56.5K – 112
2023
Q2 		$56.5K Sell
1,184
-13,685
-92% -$751K 0.02% 157
2023
Q1 		$831K Buy
+14,869
New +$441K 0.16% 190

Other funds holding HBIO

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

CM Wealth Advisors's HBIO Position: Q3 2023 in Review

CM Wealth Advisors sold out of Harvard Bioscience (HBIO) in Q3 2023, closing a stake of 1,184 shares — an estimated $56.5K sold.

CM Wealth Advisors first reported a position in HBIO in Q1 2023 and held it in 2 quarters. The position peaked at $831K in Q1 2023. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2023.

  • CM Wealth Advisors reported no remaining Harvard Bioscience position as of Q3 2023 after selling out during the quarter.
  • CM Wealth Advisors sold 1,184 Harvard Bioscience shares in Q3 2023, an estimated $56.5K.
  • CM Wealth Advisors first reported a position in Harvard Bioscience in Q1 2023 and held it in 2 quarters.
  • CM Wealth Advisors's Harvard Bioscience position peaked at $831K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2023.

Based on CM Wealth Advisors's 13F filing for Q3 2023, filed 16 Nov 2023.